Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

被引：2
|
作者：
Parrondo, Ricardo D. [1 ]
Laplant, Betsy R. [2 ]
Elliott, Jamie [1 ]
Fernandez, Andre [1 ]
Flott, Caitlin J. [1 ]
Arrington, Diedre [1 ]
Chapin, Dustin [1 ]
Brown, Jade [1 ]
Das, Saurav [1 ]
Roy, Vivek [1 ]
Chanan-Khan, Asher A. [1 ,3 ]
Ailawadhi, Sikander [1 ,3 ]
机构：
[1] Mayo Clin, Canc Ctr, Dept Hematol Oncol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Ctr Canc, Dept Canc Biol, Jacksonville, FL 32224 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01134-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [11] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [12] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
  • [13] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Weisel, Katja
    Bentur, Ohad
    Van Domelen, Dane
    Boccadoro, Mario
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
  • [14] Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Shelat, Suresh G.
    Robbins, Michael
    Rafferty, Brian
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19): : 1811 - 1822
  • [15] Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma
    Kumar, Anupama
    Rosenberg, Aaron
    Padilla, Michelle
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Shah, Nina
    Mulroney, Carolyn
    Ball, Edward
    Costello, Caitlin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S175
  • [16] Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma
    Costello, Caitlin
    Ball, Edward
    Mulroney, Carolyn
    Padilla, Michelle
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E360 - E360
  • [17] A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma
    Mikhael, Joseph R.
    Roy, Vivek
    Richardson, Paul G.
    Jakubowiak, Andrzej
    Laumann, Kristina
    LaPlant, Betsy R.
    Dispenzieri, Angela
    Rajkumar, S. Vincent
    Fonseca, Rafael
    Leung, Nelson
    Buadi, Francis
    Bergsagel, Leif
    Kyle, Robert
    Witzig, Thomas E.
    Reeder, Craig
    Lust, John A.
    Russell, Stephen
    Hayman, Suzanne R.
    Kumar, Shaji K.
    Dingli, David
    Ansell, Stephen M.
    Dalton, Robert
    Lin, Yi
    Sher, Taimur
    Kapoor, Prashant
    McCurdy, Arleigh
    Chanan-Khan, Asher
    Stewart, A. Keith
    Gertz, Morie A.
    Lacy, Martha Q.
    BLOOD, 2013, 122 (21)
  • [18] Treatment of multiple Myeloma with Elotuzumab plus Pomalidomide and Dexamethasone
    Rasche, L.
    Einsele, H.
    Nitschmann, S.
    INTERNIST, 2019, 60 (06): : 658 - 660
  • [19] Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
    Eleutherakis-Papaiakovou, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (11) : 921 - 928
  • [20] A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma
    Rosenzweig, Michael
    Sanchez, James
    Chowdhury, Arnab
    Nathwani, Nitya
    Janakiram, Murali
    Htut, Myo
    Sahebi, Firoozeh
    Walker, Tricia
    Pichiorri, Flavia
    Palmer, Joycelynne
    Krishnan, Amrita
    Keats, Jonathan
    Rosen, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S153 - S153
12345